Search alternatives:
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), clinical areas (Expand Search)
significant risks » significant risk (Expand Search), significant results (Expand Search), significant role (Expand Search)
linear decrease » linear increase (Expand Search)
risks decrease » sizes decrease (Expand Search), visits decreased (Expand Search), rivers decreased (Expand Search)
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), clinical areas (Expand Search)
significant risks » significant risk (Expand Search), significant results (Expand Search), significant role (Expand Search)
linear decrease » linear increase (Expand Search)
risks decrease » sizes decrease (Expand Search), visits decreased (Expand Search), rivers decreased (Expand Search)
-
1
The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin...
Published 2025“…Any within or between contraceptive group androgenic effects on behavior in the brain are likely dominated by the androgenic activities of MPA and NET and not by the decreased endogenous testosterone levels. The clinical trial was registered with the Pan African Clinical Trials Registry (PACTR 202009758229976)</p>…”
-
2
Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx
Published 2025“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”
-
3
Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx
Published 2025“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: -
13
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
Published 2025Subjects: -
14
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
Published 2025Subjects: -
15
-
16
-
17
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
18
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
19
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
Published 2025Subjects: -
20